Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Heat Biologics, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced the launch of its wholly-owned subsidiary, Skunkworx Bio, Inc. (“Skunkworx”), focused on the ...
read more
Tuesday, December 21, 2021
Heat Biologics, Inc. a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense ...
read more
Heat Biologics, Inc. is changing the name of the company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company’s evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from ...
read more
Heat Biologics, Inc. has unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.
read more
Heat Biologics, Inc. announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of Kansas and local and university affiliates, to support the development of a new biodefense-focused ...
read more
Albumedix and Hebei Changshan Biochem Pharma Co., Ltd (Changshan) today announced that they have entered into a supply agreement for the development of a novel type II diabetes treatment that enables once-weekly dosing.
read more
HedgePath Pharmaceuticals (HPPI) has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited under which Mayne Pharma will invest $2.5M in HPPI in a private common stock and warrant financing.
read more
Heidelberg has signed a Master Service Agreement with ProBioGen for the antibodies used in two of their pipeline ATAC molecules.
read more
Thursday, December 27, 2018
Helsinn and Menarini announced that Berlin Chemie AG, the German company of the Menarini Group, has been granted exclusive licensing rights to commercialize Pracinostat worldwide.
read more
Wednesday, August 02, 2017
Helsinn and MEI Pharma announced the first patient has been dosed in the Phase 3 study of pracinostat in combination with azacitidine in adults with newly diagnosed AML who are unfit to receive intensive induction chemotherapy.
read more
Helsinn and MEI Pharma announced findings from a genetic mutation analysis of patients in a Phase II clinical study of the investigational drug pracinostat and azacitidine in AML.
read more
HemaCare has expanded its portfolio of GMP-compliant cellular material with the launch of the GMPrime cryopreserved leukopak.
read more
HemaCare has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers.
read more
Wednesday, November 20, 2019
HemaCare has expanded its portfolio of GMP-compliant cellular material with the launch of GMPrime bone marrow aspirate.
read more
HemaCare has signed a long term lease to relocate its operations and corporate headquarters to a larger nearby site in the San Fernando Valley.
read more